title: The effect of erythropoietin against oxidative damage associated with reperfusion following ovarian detorsion.
abstract: OBJECTIVE
  To determine the effect of recombinant erythropoietin on serum oxidants and the viability of ischemic ovaries after detorsion.
  
  
  METHODS
  A non-randomized single-blind clinical trial was conducted from December 2009 to January 2011 in a University Teaching Hospital affiliated with the School of Medicine, Tabriz University of Medical Sciences. Surgery was carried out on 40 patients, aged 18-35 years, with signs and symptoms of ovarian torsion. The patients were divided into two equal groups: group 1 received recombinant erythropoietin 150 IU/kg subcutaneously during the operation and 72 h after detorsion, and group 2 received no medication. Blood samples were taken before and 72 h after detorsion to determine the plasma levels of malondialdehyde, xanthine oxidase, glutathione, superoxide dismutase, nitric oxide, and total antioxidants. In both groups, the arterial and venous blood supply of the ovary and arterial blood flow resistance were evaluated before surgery and 72 h after detorsion of the ovary. The main outcome measures were improving ovarian blood flow and reducing oxidative damage. SPSS 17.0 was used for statistical analyses.
  
  
  RESULTS
  The levels of malondialdehyde, glutathione, superoxide dismutase, nitric oxide, and total antioxidants 72 h after detorsion were significantly different between the interventional and non-interventional groups (p<0.001). There was no significant difference in the levels of xanthine oxidase (p=0.13). The difference between groups in the blood flow of the ovary 72 h after surgery was not statistically significant (p=0.61).
  
  
  CONCLUSIONS
  Recombinant erythropoietin was effective in reducing the oxidative damage of ovarian torsion.
authors.affiliation: Women's Reproductive Health Research Center, Department of Obstetrics & Gynecology, Alzahra Teaching Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. manizheh.sayyahmelli@gmail.com
authors.forename: Manizheh
authors.initials: M
authors.lastname: Sayyah-Melli
authors.forename: Mohammad-Reza
authors.initials: MR
authors.lastname: Rashidi
authors.forename: Mohaddeseh
authors.initials: M
authors.lastname: Kaseb-Ganeh
authors.forename: Nadereh
authors.initials: N
authors.lastname: Rashtchizadeh
authors.forename: Simin
authors.initials: S
authors.lastname: Taghavi
authors.forename: Elaheh
authors.initials: E
authors.lastname: Ouladsahebmadarek
authors.forename: Morteza
authors.initials: M
authors.lastname: Ghojazadeh
mesh_terms: D000293:Adolescent; D000328:Adult; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010049:Ovarian Diseases / Q000601:surgery*; D018384:Oxidative Stress / Q000187:drug effects; D011183:Postoperative Complications / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D015427:Reperfusion Injury / Q000517:prevention & control*; D014102:Torsion Abnormality / Q000601:surgery*; D055815:Young Adult
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin